相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis
Max C. Petersen et al.
JOURNAL OF CYSTIC FIBROSIS (2022)
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant
Gregory S. Sawicki et al.
JOURNAL OF CYSTIC FIBROSIS (2022)
The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis
Kevin J. Scully et al.
JOURNAL OF CYSTIC FIBROSIS (2022)
A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus
Sylvia Szentpetery et al.
JOURNAL OF CYSTIC FIBROSIS (2022)
Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis-An Observational Pilot Study
Insa Korten et al.
FRONTIERS IN PEDIATRICS (2022)
Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation Results of a Two-Part Phase 3 Clinical Trial
Jane C. Davies et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
Lumacaf tor/ivacaf tor therapy fails to increase insulin secretion in F508del/F508del CF patients
Amir Moheet et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation
Jane C. Davies et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
Effect of CFTR modulator therapy on cystic fibrosis-related diabetes
Holly Gaines et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2021)
Expression of miRNA-29 in Pancreatic β Cells Promotes Inflammation and Diabetes via TRAF3
Yi Sun et al.
CELL REPORTS (2021)
Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion
C. Colombo et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2021)
Cystic fibrosis-related diabetes and lung disease: an update
Bernadette J. Prentice et al.
EUROPEAN RESPIRATORY REVIEW (2021)
Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy
Christopher N. Fortner et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study
Jordana E. Hoppe et al.
LANCET RESPIRATORY MEDICINE (2021)
Impaired glucose tolerance and indeterminate glycemia in cystic fibrosis
Nader Kasim et al.
JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY (2021)
Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study
Mark Chilvers et al.
LANCET RESPIRATORY MEDICINE (2021)
Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries
Nataliya Volkova et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
In Situ Analysis Reveals That CFTR Is Expressed in Only a Small Minority of β-Cells in Normal Adult Human Pancreas
Michael G. White et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Glucose abnormalities detected by continuous glucose monitoring are common in young children with Cystic Fibrosis
Bernadette J. Prentice et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients
Bastien Misgault et al.
JOURNAL OF CYSTIC FIBROSIS (2020)
Heterogeneous expression of CFTR in insulin-secreting β-cells of the normal human islet
Mauricio Di Fulvio et al.
PLOS ONE (2020)
The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis
Valentine Sergeev et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2020)
Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy
Andrea Kelly et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Continuous glucose monitoring in youth with cystic fibrosis treated with lumacaftor-ivacaftor
Angel Li et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Lumacaftor-rescued F508del-CFTR has a modified bicarbonate permeability
Loretta Ferrera et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis
Xingshen Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Early glucose abnormalities are associated with pulmonary inflammation in young children with cystic fibrosis
Bernadette J. Prentice et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Survival in a bad neighborhood: pancreatic islets in cystic fibrosis
Andrew W. Norris et al.
JOURNAL OF ENDOCRINOLOGY (2019)
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis
Seth Walker et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Harry G. M. Heijerman et al.
LANCET (2019)
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
P. G. Middleton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis-Related Diabetes
Francis Christian et al.
JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS (2019)
Effect of Lumacaftor/Ivacaftor on glucose metabolism and insulin secretion in Phe508del homozygous cystic fibrosis patients
Jan C. Thomassen et al.
JOURNAL OF CYSTIC FIBROSIS (2018)
Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline
Christine L. Chan et al.
JOURNAL OF CYSTIC FIBROSIS (2018)
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
Leona Bessonova et al.
THORAX (2018)
Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial
Manfred Ballmann et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study
Margaret Rosenfeld et al.
LANCET RESPIRATORY MEDICINE (2018)
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Dominic Keating et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cystic fibrosis-related diabetes is caused by islet loss and inflammation
Nathaniel J. Hart et al.
JCI INSIGHT (2018)
CFTR Influences Beta Cell Function and Insulin Secretion Through Non-Cell Autonomous Exocrine-Derived Factors
Xingshen Sun et al.
ENDOCRINOLOGY (2017)
Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation
Venkateshwar Mutyam et al.
JOURNAL OF CYSTIC FIBROSIS (2017)
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Steven M. Rowe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience
Adi Dagan et al.
RESPIRATORY MEDICINE (2017)
Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled, phase 3 trial
Felix Ratjen et al.
LANCET RESPIRATORY MEDICINE (2017)
Impact of CFTR Modulation on Intestinal pH, Motility, and Clinical Outcomes in Patients With Cystic Fibrosis and the G551D Mutation
Daniel Gelfond et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2017)
Abnormal Glucose Tolerance in Infants and Young Children with Cystic Fibrosis
Yaling Yi et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
C. E. Wainwright et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
CFTR potentiator therapy ameliorates impaired insulin secretion in CF patients with a gating mutation
Reuven Tsabari et al.
Journal of Cystic Fibrosis (2015)
Resolution of Cystic Fibrosis-related Diabetes with lvacaftor Therapy
Don Hayes et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
CFTR and Anoctamin 1 (ANO1) contribute to cAMP amplified exocytosis and insulin secretion in human and murine pancreatic beta-cells
Anna Edlund et al.
BMC MEDICINE (2014)
Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients
A. Leclercq et al.
JOURNAL OF CYSTIC FIBROSIS (2014)
Glucose-induced electrical activities and insulin secretion in pancreatic islet β-cells are modulated by CFTR
Jing Hui Guo et al.
NATURE COMMUNICATIONS (2014)
Genetic Modifiers of Cystic Fibrosis-Related Diabetes
Scott M. Blackman et al.
DIABETES (2013)
Insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot study
Melena D. Bellin et al.
PEDIATRIC DIABETES (2013)
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Bonnie W. Ramsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Epidemiology, Pathophysiology, and Prognostic Implications of Cystic Fibrosis-Related Diabetes A technical review
Antoinette Moran et al.
DIABETES CARE (2010)
Impaired Fasting Glucose in Cystic Fibrosis
Brigitte I. Frohnert et al.
DIABETES CARE (2010)
Clinical Care Guidelines for Cystic Fibrosis-Related Diabetes A position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society
Antoinette Moran et al.
DIABETES CARE (2010)
Natural History of Glucose Intolerance in Patients with Cystic Fibrosis: Ten-Year Prospective Observation Program
Anca E. Sterescu et al.
JOURNAL OF PEDIATRICS (2010)
Oral glucose tolerance testing in children with cystic fibrosis
Katie Larson Ode et al.
PEDIATRIC DIABETES (2010)
Cytokines in the Progression of Pancreatic beta-Cell Dysfunction
Chunjiong Wang et al.
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (2010)
Cystic Fibrosis-Related Diabetes: Current Trends in Prevalence, Incidence, and Mortality
Antoinette Moran et al.
DIABETES CARE (2009)
Inflammation and insulin resistance
Carl de Luca et al.
FEBS LETTERS (2008)
Glucose tolerance, insulin secretion, and insulin sensitivity in children and adolescents with cystic fibrosis and no prior history of diabetes
Deborah A. Elder et al.
JOURNAL OF PEDIATRICS (2007)
New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis
C Mueller-Brandes et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Insulin-secretion abnormalities and clinical deterioration related to impaired glucose tolerance in cystic fibrosis
S Tofé et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
分享论文
